NEW ENTERPRISE ASSOCIATES 16, L.P. - ARSANIS, INC. 13D

Company

X4 Pharmaceuticals, Inc

Filed

November 29, 2017

Accession Number

0001072613-17-000603

A Schedule 13D is filed when an investor acquires more than 5% of a company's shares with an intent to influence control. Learn more about SC 13D filings →